Patience Needed On US Biosimilars, Says Samsung Bioepis’ Ko

Expectations For US Biosimilars ‘May Have Been Excessive’

 
• By David Wallace
Hourglass
The US biosimilars market will take time to mature, Ko insists • Source: Shutterstock

More from Strategy

More from Business